title: [A case of Stevens-Johnson syndrome (SJS) progressive toxic epidermal necrolysis (TEN) onset during hyposensitization therapy for pulmonary tuberculosis complicated with dermatomyositis].
abstract: A 58-year-old female with a history of dermatomyositis was receiving large oral doses of steroids. She had pulmonary tuberculosis and developed a fever, systemic exudative erythema, exanthema, and epidermolysis covering 30% of her body surface area while being treated with four agents, including isoniazid (INH) and rifampicin (RFP). Histopathologically, eosinophilic necrosis was observed in all layers of the epidermis and a diagnosis of Stevens-Johnson syndrome (SJS) progressive toxic epidermal necrolysis (TEN) was made. The drugs suspected in the drug-induced lymphocyte stimulation test (DLST) re-testing were INH and RFP, and the DLST was considered to be important during the recovery period as well as in the acute phase. Early treatment with plasma exchange therapy and large quantities of intravenous immunoglobulin (IVIG) was successful. Plasma exchange therapy and IVIG are extremely effective when SJS and TEN occur in a patient already on high-dose steroid therapy. Note that the incidence of SJS and TEN is believed to be higher in patients with collagen disease, such as in our case, as compared to the general population.
authors.affiliation: Division of Rheumatology, National Center for Global and Health Medicine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamashita
authors.forename: Yo
authors.initials: Y
authors.lastname: Ueda
authors.forename: Yuko
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Akio
authors.initials: A
authors.lastname: Mimori
mesh_terms: D003882:Dermatomyositis / Q000150:complications / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000009:adverse effects*; D005076:Exanthema / Q000150:complications / Q000628:therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007538:Isoniazid / Q000627:therapeutic use; D008875:Middle Aged; D010951:Plasma Exchange; D012293:Rifampin / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000628:therapy
chemical_list: D016756:Immunoglobulins, Intravenous; D007538:Isoniazid; D012293:Rifampin